Vontobel Holding Ltd. Has $748,000 Stock Holdings in Encompass Health Co. (NYSE:EHC)

Vontobel Holding Ltd. lessened its stake in Encompass Health Co. (NYSE:EHC) by 11.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,740 shares of the company’s stock after selling 1,021 shares during the quarter. Vontobel Holding Ltd.’s holdings in Encompass Health were worth $748,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. UMB Bank n.a. lifted its position in Encompass Health by 387.7% in the third quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after purchasing an additional 252 shares during the period. Oakworth Capital Inc. bought a new stake in shares of Encompass Health in the 2nd quarter worth about $40,000. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Encompass Health by 58.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock worth $46,000 after purchasing an additional 198 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Encompass Health by 31.9% in the 1st quarter. GAMMA Investing LLC now owns 616 shares of the company’s stock worth $51,000 after purchasing an additional 149 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Encompass Health in the 2nd quarter worth about $58,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Insider Transactions at Encompass Health

In other news, CFO Douglas E. Coltharp sold 12,260 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the transaction, the chief financial officer now directly owns 136,227 shares of the company’s stock, valued at $11,761,839.18. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Leerink Partnrs upgraded shares of Encompass Health to a “strong-buy” rating in a research report on Wednesday, July 10th. Truist Financial increased their target price on Encompass Health from $104.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. KeyCorp started coverage on Encompass Health in a research note on Friday, October 11th. They set an “overweight” rating and a $115.00 target price for the company. Stephens reissued an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada raised their price target on shares of Encompass Health from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. Eight equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $104.67.

Encompass Health Price Performance

Encompass Health stock opened at $97.19 on Monday. The stock’s 50 day moving average is $92.85 and its 200 day moving average is $87.85. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.35 and a quick ratio of 1.35. The firm has a market cap of $9.79 billion, a P/E ratio of 26.27, a P/E/G ratio of 1.43 and a beta of 0.88. Encompass Health Co. has a one year low of $57.55 and a one year high of $98.74.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Monday, August 5th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.10. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.30 billion. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.95 earnings per share. As a group, research analysts expect that Encompass Health Co. will post 4.18 EPS for the current year.

Encompass Health announced that its Board of Directors has initiated a stock buyback program on Wednesday, July 24th that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to reacquire up to 5.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date is Thursday, January 2nd. Encompass Health’s payout ratio is 18.38%.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.